Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company renowned for its pioneering work in predictive computational drug target discovery powered by artificial intelligence and machine learning, has announced its upcoming third-quarter financial results for 2025. Scheduled for release on Monday, November 10, 2025, the report will be made available before the U.S. financial markets open. Management will conduct a conference call and webcast at 8:30 AM ET to discuss the results and offer insights into the company’s strategic direction.

Compugen is at the forefront of cancer treatment innovation, utilizing its proprietary Unigen™ platform to identify new drug targets and biological pathways that could lead to groundbreaking immunotherapies. The company is advancing two key proprietary candidates in Phase 1 development: COM701, an anti-PVRIG antibody that holds the promise of being a first-in-class therapy, and COM902, which targets TIGIT and is viewed as a potential best-in-class solution for solid tumors.

Additionally, Rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, is currently in Phase 3 development through a licensing agreement with AstraZeneca. Another noteworthy asset, GS-0321 (previously COM503), a promising high-affinity anti-IL-18 binding protein antibody, is progressing through Phase 1 trials under a license to Gilead. Compugen’s portfolio is further bolstered by a variety of early-stage immuno-oncology research programs aimed at exploring novel mechanisms to engage the immune system against cancer.

Headquartered in Israel with a presence in San Francisco, Compugen is publicly traded on both Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Investors and stakeholders will find this upcoming earnings call instrumental in gaining insights into the company's performance and strategic initiatives.

As Compugen Ltd. prepares to release its third-quarter 2025 results on November 10, investors should closely monitor key performance indicators and updates from their Phase 1 and Phase 3 clinical trials. The outcomes of these trials are pivotal, as they involve significant assets such as COM701 and COM902, both positioned in the competitive landscape of cancer immunotherapy. Given the rising focus on advanced treatments within oncology, positive data releases could catalyze investor sentiment and near-term price volatility for CGEN shares.

Analysts should take note of any updates on the progression of AstraZeneca's bispecific antibody, Rilvegostomig, particularly regarding patient enrollment, safety data, and any interim results from the Phase 3 study. Additionally, clarity on partnership developments, especially concerning Gilead's collaboration on GS-0321, will be crucial as it could affect future revenue streams and validate Compugen's computational drug discovery model.

From a financial perspective, it’s essential to evaluate Compugen’s cash position and burn rate, especially in the context of their pipeline expenditures. Analysts should monitor any guidance provided during the earnings call, particularly relating to projected timelines for clinical milestones and potential future funding needs. A lack of sufficient cash runway could adversely impact share value if investors sense challenges in executing their clinical strategy.

Investors may consider a cautious approach leading up to the earnings announcement, given the inherent volatility associated with healthcare stocks, particularly those dependent on clinical trial outcomes. In the event of favorable results, we could see a significant uptick in stock value, whereas any negative news could lead to downward pressure. Thus, staying informed and strategically reactive to developments around Compugen's catalysts will be key in navigating the investment landscape in the lead-up to the earnings announcement.